Mangoceuticals (MGRX) CFO reports insider sale of 3,333 shares

Rhea-AI Filing Summary

Mangoceuticals, Inc. reported an insider stock transaction by its Chief Financial Officer. On 12/15/2025, the CFO sold 3,333 shares of the company’s common stock at a price of $1.1653 per share. After this sale, the CFO beneficially owned 120,000 shares, held directly. The filing reflects a routine update of the officer’s ownership position and does not list any derivative securities transactions.

Insider Trade Summary

Net Seller: 3,333 shares

Net Sell 1 txn

Insider JOHNSTON EUGENE M

Role CFO

Sold 3,333 shs ($4K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,333	$1.1653	$4K

Holdings After Transaction: Common Stock — 120,000 shares (Direct)

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 12/17/2025 - 05:00 PM Learn about SEC filing dates

FAQ

What insider transaction did Mangoceuticals (MGRX) disclose in this Form 4?

Mangoceuticals disclosed that its Chief Financial Officer sold 3,333 shares of common stock on 12/15/2025 at a price of $1.1653 per share.

Who is the reporting person in the Mangoceuticals (MGRX) Form 4 filing?

The reporting person is the Chief Financial Officer of Mangoceuticals, Inc., who is an officer of the company and files individually.

How many Mangoceuticals (MGRX) shares does the CFO own after the transaction?

After the reported sale, the CFO beneficially owned 120,000 shares of Mangoceuticals common stock, held in direct ownership.

What was the sale price of Mangoceuticals (MGRX) shares in this insider transaction?

The 3,333 shares of Mangoceuticals common stock were sold at a price of $1.1653 per share on 12/15/2025.

Does this Mangoceuticals (MGRX) Form 4 report any derivative securities?

No derivative securities transactions are reported in this filing; only a sale of common stock is listed in Table I.

Is the Mangoceuticals (MGRX) Form 4 filed by one or multiple reporting persons?

The Form 4 is filed by one reporting person, the company’s Chief Financial Officer, rather than by a group.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

JOHNSTON EUGENE M

(Last) (First) (Middle)

C/O MANGOCEUTICALS, INC.

17130 DALLAS PKWY STE 240

(Street)

DALLAS TX 75248

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MANGOCEUTICALS, INC. [ MGRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO

3. Date of Earliest Transaction (Month/Day/Year)
12/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/15/2025		S		3,333	D	$1.1653	120,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Eugene M Johnston	12/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.